LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

19.94 1.22

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.7

Massimo

20.54

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+101.87% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-149M 1.7B
Apertura precedente	18.72
Chiusura precedente	19.94

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

9.91 / 14.15 Supporto e resistenza

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 mag 2026, 16:33 UTC

Utili

I principali Market Mover

Webull Shares Slide on 1Q Loss, Soaring Costs

22 mag 2026, 21:10 UTC

Utili

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 19:47 UTC

Utili

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mag 2026, 19:17 UTC

Discorsi di Mercato

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 mag 2026, 18:54 UTC

Discorsi di Mercato

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mag 2026, 18:38 UTC

Discorsi di Mercato

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mag 2026, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mag 2026, 18:09 UTC

Discorsi di Mercato

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mag 2026, 17:58 UTC

Discorsi di Mercato

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 17:54 UTC

Discorsi di Mercato

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 mag 2026, 17:03 UTC

Discorsi di Mercato

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 mag 2026, 16:54 UTC

Discorsi di Mercato

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

22 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2026, 16:16 UTC

Discorsi di Mercato

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

22 mag 2026, 15:55 UTC

Discorsi di Mercato

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

22 mag 2026, 15:42 UTC

Discorsi di Mercato

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 mag 2026, 15:35 UTC

Discorsi di Mercato

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

101.87% in crescita

Previsioni per 12 mesi

Media 39.91 USD 101.87%

Alto 57 USD

Basso 29 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

9.91 / 14.15Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.